Inhaled treprostinil solution for Pulmonary Hypertension (PERFECT OLE Trial)

"At this moment, there are 9 ongoing clinical trials for Inhaled treprostinil solution in 101 different cities and 6 nations. The first ever such study was completed in 2015, 70 people took part in it, and United Therapeutics sponsored the project. 46 more trials have been completed since then."

"Inhaled treprostinil solution can be used to mitigate the effects of nyha functional class iii pulmonary arterial hypertension, as well as general NYHA functional class III and pulmonary arterial hypertension."

"There are a total of 9 ongoing clinical trials researching the effectiveness of inhaled treprostinil solution. 4 of those trials have reached Phase 3. Many of the trial locations for this treatment are based in Little Rock, Arkansas, but there are 234 centres running these tests in total."

"According to the information available on clinicaltrials.gov, this particular trial is not currently looking for new patients. The study was first posted on December 21st, 2018 and was last edited October 7th, 2022. Although this study isn't recruiting right now, there are 1277 other trials that are actively seeking participants."

"Presently, this study is not looking for more participants as it has already closed recruitment. Originally appearing on December 21st 2018 with the latest edits taking place on October 7th 2022, those affected by hypertension or pulmonary problems have 1268 and 9 other trials to respectively choose from."

"At the moment, this clinical trial is looking for patients from a total of 27 different hospitals. While some of these sites are in Atlanta, Chicago or Miami, there are also many other locations across the country. If you enroll in this program, it will be most convenient if you choose a clinic that is near to where you live to avoid having to travel too far."

"There is existing clinical evidence to support the safety of inhaled treprostinil solution, so it was given a score of 3."